New hope for Hard-to-Treat prostate cancer: Drug-Radiation combo trial launches

NCT ID NCT07451795

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining an experimental immunotherapy drug (SHR-1701) with targeted radiation can help men with metastatic castration-resistant prostate cancer, a form that no longer responds to hormone therapy. About 66 participants will receive either the drug plus radiation or radiation alone. The main goal is to see if the combination delays cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-1701 (an experimental immunotherapy drug) plus stereotactic body radiotherapy (focused radiation)
What this could lead to: If successful, this combination could offer a new way to slow the progression of advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is an early Phase 2 trial with only 66 participants, so results may not apply to everyone. The drug is experimental, and side effects from immunotherapy and radiation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) PROSTATE CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China
Fudan University Shanghai Cancer Center Xiamen Branch
RECRUITING

Xiamen, China
Fujian Cancer Hospital
RECRUITING

Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.